Some of those mistakes are highlighted in new research published online today in the Journal of the American Academy of Dermatology. Researchers set up free sunscreen dispensers at the Minnesota State Fair and observed 2,187 people using them over the course of 93 hours. Only one-third (33 percent) of people applied sunscreen to all exposed skin, and just 38 percent were wearing sun-protective clothing, hats or sunglasses. Additionally, utilization of the free sunscreen dispensers decreased significantly on cloudy days. “Research has shown that women are more likely than men to use sunscreen, but it’s vital that men use it too,” says board-certified dermatologist Darrell S. Rigel, MD, FAAD, a clinical professor in the Ronald O. Perelman Department of Dermatology at New York University. “Men over 50 have a higher risk than the general population of developing melanoma, the deadliest form of skin cancer, and UV exposure is the most preventable skin cancer risk factor, so it’s important for men of all ages to protect themselves from the sun’s harmful rays by seeking shade, wearing protective clothing and applying sunscreen.”

Journal of the American Academy of Dermatology, Volume 77, Issue 1

Comment: Studies continue to show inadequate sunscreen use despite repeated attempts in education. Applying sunscreen to all exposed skin should be a part of one’s daily regimen, similar to brushing your teeth. SPF 30 or higher is recommended. Options are available to individuals with sensitive skin. New vehicles offer choices for those individuals who complain sunscreens feel greasy or sticky.

(June 2017)

Dupilumab is an interleukin (IL)-4 receptor alpha antagonist approved by the US Food and Drug Administration (FDA) for adults with moderate to severe atopic dermatitis not adequately controlled with topical therapies. In a phase III trial of over 700 patients with moderate to severe atopic dermatitis and inadequate response to topical corticosteroids, one year of treatment with dupilumab improved symptoms relative to placebo. All patients received topical corticosteroids or topical calcineurin inhibitors. These results support the use of dupilumab for the long-term treatment of moderate to severe atopic dermatitis when topical therapies alone are insufficient and other systemic treatments are contraindicated.

Lancet. 2017;389(10086):2287

Comment: This is an exciting development for the treatment of moderate to severe eczema for which there was no adequate treatment options. This has been a life changing option for severe adult patients. Studies are now underway to seek approval for use in children under the age of 18.

(October 2017)

Two meta-analyses in 2012 and 2014 suggested that there was a modest protective effect of probiotics used in late pregnancy/early infancy on the development of eczema within the first two years of life, although subsequent trials did not confirm these findings. A recent randomized trial provides further evidence of the lack of effectiveness of probiotics for eczema prevention. In this trial, 184 high-risk infants received either Lactobacillus rhamnosus GG plus inulin or inulin alone for the first six months of life. Eczema was diagnosed by age two in approximately 30 percent of the children in both groups. We suggest not giving probiotics during pregnancy and infancy for the prevention of eczema.

Pediatrics. 2017;140(3)

Comment: Studies have shown that some patient populations may benefit from probiotics though results were highly variable and inconsistent. Dietary manipulation has been investigated and except for foods that cause obvious flares, no dietary intervention was found to be helpful.


Adult and Pediatric Dermatology
4601 W. 109th St., Suite 116  •  Overland Park, Kansas 66211  •  913-469-1115